Update on the Management of Diabetic Kidney Disease

被引：0

作者：

Luu, Lynn ^{[1
]}

Adamzadeh, Bahar ^{[1
]}

Neumiller, Joshua J. ^{[1
]}

机构：

[1] Washington State Univ, Coll Pharm & Pharmaceut Sci, Dept Pharmacotherapy, Spokane, WA 99202 USA

来源：

US PHARMACIST | 2021年 / 46卷 / 11期

关键词：

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Diabetic kidney disease (DKD) is a complication that occurs in approximately 40% of patients with type 2 diabetes. DKD is associated with significant morbidity and mortality and, additionally, complicates glycemic management. While interventions to prevent and/or slow the progression of DKD have historically been limited, agents from the sodium-glucose cotransporter-2 inhibitor, glucagon-like peptide-1 receptor agonist, and nonsteroidal mineralocorticoid receptor antagonist classes of medication offer new hope for DKD patients. Pharmacists can play a critical role as members of the care team to promote the safe and appropriate use of these kidney-protective agents in appropriate individuals to improve patient outcomes.

引用

页码：57 / 66

页数：10